Seres Therapeutics (MCRB) Given Daily News Impact Rating of 0.10

Media coverage about Seres Therapeutics (NASDAQ:MCRB) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Seres Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 46.3616386285196 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Seres Therapeutics (NASDAQ MCRB) opened at $10.08 on Thursday. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a fifty-two week low of $8.85 and a fifty-two week high of $17.42.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.22. The company had revenue of $23.00 million during the quarter, compared to the consensus estimate of $17.29 million. Seres Therapeutics had a negative return on equity of 82.11% and a negative net margin of 267.15%. Seres Therapeutics’s revenue for the quarter was up 76.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.46) EPS. equities research analysts anticipate that Seres Therapeutics will post -2.33 earnings per share for the current fiscal year.

A number of research analysts recently issued reports on the company. Zacks Investment Research lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. ValuEngine lowered Seres Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, September 21st. Citigroup assumed coverage on Seres Therapeutics in a report on Thursday, October 12th. They issued a “positive” rating and a $19.00 target price for the company. Cowen reiterated a “buy” rating on shares of Seres Therapeutics in a report on Monday, October 2nd. Finally, Oppenheimer assumed coverage on Seres Therapeutics in a report on Thursday, October 12th. They issued an “outperform” rating and a $19.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $18.00.

ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/14/seres-therapeutics-mcrb-given-daily-news-impact-rating-of-0-10.html.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Insider Buying and Selling by Quarter for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply